webinar
Novel Pharmacological Treatments for the Prevention of Cardiovascular Events
Novel Pharmacological Treatments for the Prevention of Cardiovascular Events Which agents to use and which patients benefit from the newer interventions? OVERVIEW This webinar focuses on the use of novel pharmacological treatment strategies aimed at improving cardiovascular outcomes in medium to high-risk patients. The focus will be on newer lipid lowering agents and novel antidiabetic […]
Clopidogrel or Ticagrelor: Why, When, for Whom?
Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the cornerstone of the management of acute coronary syndromes. Despite its proven benefits, the choice of P2Y12 inhibitors remains to be debated over the decades because of the differences in efficacy and safety profiles among these agents. In this 60-minute session by the […]
Nebivolol: No limb pain?
Beta-blockers are routinely prescribed often as first-line therapy for various cardiovascular diseases such as coronary heart disease and heart failure. Much of their prescribing relates to the benefits of the newer generation of beta-blockers and greater cardio-selectivity. One of the challenges all clinicians face is to manage the choice of numerous beta-blockers and in particular […]
Decongesting the current diuretic landscape in Heart Failure
We are finally back with the second round of our webinar series A to Z of Cardiovascular Pharmacotherapy. Our first session will be titled "Decongesting the current diuretic landscape in Heart Failure" and will be broadcasted live on Wednesday 6th March 2024 at 12.30 GMT. It will be a 1-hour live webinar covering diuretic selection and […]